My SciELO
Custom servicesServices on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Revista Española de Salud Pública
On-line version ISSN 2173-9110Print version ISSN 1135-5727
Abstract
ALFAGEME ROLDAN, Fernando; BERMEJO HERNANDO, Almudena; CALVO GONZALEZ, José Luís and MARQUES SANCHEZ, Pilar. Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks. Rev. Esp. Salud Publica [online]. 2016, vol.90, e30001. Epub June 07, 2021. ISSN 2173-9110.
Background:
The objective was to evaluate the efficiency (relation between the cost and the results in health) of the treatments in psoriasis, seeking a higher quality of economic evaluations, consistency and transparency in these studies.
Methods:
We developed a model of economic evaluation in psoriasis collecting all the many direct and indirect costs of each treatment. The effectiveness indicator used was Psoriasis Area Severity Index [PASI 75] which is generally acceptable in studies of psoriasis. The effectiveness indicator was a PASI 75. Subsequently we calculated the Incremental Cost-Effectiveness Ratio (ICER) for the period of 12 weeks and PASI 75, ordering treatments by level of effectiveness at the expense of treatment costs.
Results:
The most cost effective treatment was methotrexate (ICER -7.5) followed by acitretin (ICER 29.5). The least cost has proved effective PUVA (ICER 4,651), followed by UVB narrow band (2,886.1).
Conclusions:
When taking into account both direct and indirect costs together with efficiency, methotrexate is the most cost effective treatment.
Keywords : Psoriasis; Cost-Effectiveness Analysis; Methotrexate; Adalimumab; Infliximab; Ustekinumab; Economic evaluation.
